Yahoo! Finance: AMGN News

Amgen resolves patent dispute with Roche (at bizjournals.com)

Wed, 23 Dec 2009 17:05:13 Etc/GMT

Deals from Pfizer, Novartis and AstraZeneca. Also: Snake Oil. (at The Wall Street Journal Online)

Wed, 23 Dec 2009 17:00:33 Etc/GMT

InPlay: Amgen pushes as high as 57.67 in early trade leaving it just under a resistance zone at its Nov/Dec highs at 57.73/57.88 (Briefing.com)

Wed, 23 Dec 2009 14:48:26 Etc/GMT

[$$] Court Rules Roche Anemia Drug Infringes Amgen Patent (at The Wall Street Journal Online)

Wed, 23 Dec 2009 02:58:44 Etc/GMT

Amgen says court blocks rival Roche anemia drug (AP)

Tue, 22 Dec 2009 23:39:53 Etc/GMT

Swiss drugmaker Roche will not be allowed to sell its anemia drug Mircera in the U.S. until July 2014 under terms of a settlement with Amgen Inc., the companies said Tuesday.

UPDATE - Amgen wins anemia drug patent dispute with Roche (at Reuters)

Tue, 22 Dec 2009 21:49:10 Etc/GMT

Amgen Resolves EPO Patent Dispute With Roche (PR Newswire)

Tue, 22 Dec 2009 21:04:00 Etc/GMT

Amgen announced today that the United States District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting Roche from infringing Amgen's patents on recombinant erythropoietin , thus bringing the five-year patent infringement dispute to an end. Today's judgment was accompanied by Roche's admission that the five Amgen EPO patents involved in the lawsuit are valid, enforceable and infringed by Roche's pegylated-erythropoietin product, MIRCERA and by Amgen allowing Roche to begin selling MIRCERA in the U.S. in mid-2014 under terms of a limited license agreement. The settlement terms do not include any financial payments between the parties.

Some Incyte Into Why These Drugs Rock (at Motley Fool)

Tue, 22 Dec 2009 18:16:07 Etc/GMT

2009 Biotech Cheers and Jeers (at Motley Fool)

Tue, 22 Dec 2009 16:36:24 Etc/GMT

5 Top Stocks at Half Price (at Motley Fool)

Tue, 22 Dec 2009 16:11:40 Etc/GMT

Rigel Pharma Gives Up Gains (at Barrons.com)

Mon, 21 Dec 2009 21:49:00 Etc/GMT

Amgen Closer to Prolia Approval (Zacks.com)

Mon, 21 Dec 2009 21:43:15 Etc/GMT

We believe Prolia has the potential to capture a major share of the osteoporosis market once launched.

Nelson becomes major player in health-care deal (at MarketWatch)

Mon, 21 Dec 2009 21:19:00 Etc/GMT

It seems there's another oracle in Omaha.

Monday Options Recap (at Seeking Alpha)

Mon, 21 Dec 2009 20:52:27 Etc/GMT

Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines (PR Newswire)

Fri, 18 Dec 2009 21:40:00 Etc/GMT

Amgen announced today that Roger M. Perlmutter, M.D., Ph. D., Amgen's executive vice president of Research & Development, has been elected a 2009 Fellow of the American Association for the Advancement of Science .

Buy a Company, Get the Plant for Free (at Motley Fool)

Fri, 18 Dec 2009 20:43:15 Etc/GMT

Amgen's Next Big Thing Gets a Thumbs Up in Europe (at The Wall Street Journal Online)

Fri, 18 Dec 2009 16:18:51 Etc/GMT

Buy Gilead, Ignore Study (TheStreet.com TV)

Fri, 18 Dec 2009 14:41:58 Etc/GMT

http://us.news2.yimg.com/us.yimg.com/p/fi/26/51/25.jpg/yfinance/tscm/strategysession/10648659http://www.thestreet.com/

[video] Buy Gilead, Ignore Study (at TheStreet.com)

Fri, 18 Dec 2009 14:00:00 Etc/GMT

UPDATE - European experts recommend Amgen, Glaxo bone drug (at Reuters)

Fri, 18 Dec 2009 13:59:32 Etc/GMT